Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Mini-Review Article

Role of Conventional and Novel Classes of Diuretics in Various Diseases

Author(s): Nitika Yadav*, Neelottama Kushwaha, Swatantra K.S. Kushwaha and Priyank Yadav

Volume 20, Issue 2, 2025

Published on: 24 January, 2024

Page: [135 - 148] Pages: 14

DOI: 10.2174/0115748855282746231208072819

Price: $65

Abstract

Diuretics are advised as the initial course of action for hypertension because they are successful in lowering hypervolemia and resolving electrolyte abnormalities. The most popular diuretics are included with their main characteristics in this summary. The primary line of treatment for common cardiovascular and non-cardiovascular diseases is diuretics. Patients with hypertension, oedema, heart failure, as well as a variety of renal disorders are frequently treated with conventional diuretics. The usage of the various types of diuretics that are now licensed for therapeutic use generally has a favourable risk/benefit ratio. Nevertheless, they are not without drawbacks. Pharmaceutical scientists have thus been working to develop new drugs with an enhanced pharmacological profile. SGLT2 inhibitors (sodium-glucose-linked cotransporter 2 inhibitors) have altered how hypoglycaemic medications are thought to affect heart failure. Despite the presence or absence of diabetes, the sodiumglucose- linked cotransporter subtype 2-inhibitor class, which was first developed as a therapy for T2DM (Type 2 Diabetes mellitus), has shown considerable promise in lowering cardiovascular risk, particularly in relation to heart failure (HF) outcomes. The immediate and substantial improvements observed in clinical studies do not appear to be attributable to the drug's fundamental mechanism, which involves inducing glycosuria and diuresis by blocking receptors in the renal nephron. Among patients with chronic heart failure and cirrhosis, hyponatremia is a risk factor for death.

Keywords: Diuretics, hypertension, Covid-19, glaucoma, diabetes mellitus, novel class of diuretics.

Graphical Abstract
[1]
Ba K, Sow MA, Magne J. Risk of amputation under diuretics in patients with or at risk of lower extremity arterial disease: A systematic review and meta-analysis. Arch Cardiovasc Dis 2023; 116(6-7): 357-63.
[http://dx.doi.org/10.1016/j.acvd.2023.04.002]
[2]
Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol 2019; 14(8): 1248-57.
[http://dx.doi.org/10.2215/CJN.09630818] [PMID: 30936153]
[3]
Keller F, Hann A. Clinical pharmacodynamics. Clin J Am Soc Nephrol 2018; 13(9): 1413-20.
[http://dx.doi.org/10.2215/CJN.10960917] [PMID: 29769182]
[4]
Li M, Zhang S, Yang B. Urea transporters identified as novel diuretic drug targets. Curr Drug Targets 2020; 21(3): 279-87.
[http://dx.doi.org/10.2174/1389450120666191129101915] [PMID: 31782365]
[5]
Manolis A, Kallistratos M, Doumas M. Torasemide in hypertension and heart failure: Re-inventing loop diuretic therapy. Curr Pharm Des 2021; 27(23): 2714-21.
[http://dx.doi.org/10.2174/1381612827666210406142933] [PMID: 33823773]
[6]
Titko T, Perekhoda L, Drapak I, Tsapko Y. Modern trends in diuretics development. Eur J Med Chem 2020; 208: 112855.
[http://dx.doi.org/10.1016/j.ejmech.2020.112855] [PMID: 33007663]
[7]
Gotoh K, Shibata H. Aldosterone: History and introduction. In: In Textbook of Nephro-Endocrinology. 2nd ed.Academic Press 2018; pp. 465-76.
[8]
Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21(2): 137-55.
[http://dx.doi.org/10.1002/ejhf.1369] [PMID: 30600580]
[9]
Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75(10): 1178-95.
[http://dx.doi.org/10.1016/j.jacc.2019.12.059] [PMID: 32164892]
[10]
Natsis M, Antza C, Doundoulakis I, Stabouli S, Kotsis V. Hypertension in obesity: Novel insights. Curr Hypertens Rev 2020; 16(1): 30-6.
[http://dx.doi.org/10.2174/18756506OTgwfNzgcTcVY] [PMID: 30987571]
[11]
Ishikawa S, Naito S, Iimori S, et al. Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease. PLoS One 2018; 13(2): e0192990.
[http://dx.doi.org/10.1371/journal.pone.0192990] [PMID: 29447254]
[12]
Minegishi S, Luft FC, Titze J, Kitada K. Sodium handling and interaction in numerous organs. Am J Hypertens 2020; 33(8): 687-94.
[http://dx.doi.org/10.1093/ajh/hpaa049] [PMID: 32198504]
[13]
Martins VM, Ziegelmann PK, Helal L, et al. Thiazide diuretics alone or in combination with a potassium-sparing diuretic on blood pressure-lowering in patients with primary hypertension: Protocol for a systematic review and network meta-analysis. Syst Rev 2022; 11(1): 23.
[http://dx.doi.org/10.1186/s13643-022-01890-y] [PMID: 35135630]
[14]
Rahimi K, Bidel Z, Nazarzadeh M, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: An individual participant-level data meta-analysis. Lancet 2021; 397(10285): 1625-36.
[http://dx.doi.org/10.1016/S0140-6736(21)00590-0] [PMID: 33933205]
[15]
Bernardi LS, Júnior PNS, Barreto BIF, et al. Determination of hydrochlorothiazide and two major degradation products by stability indicating high performance liquid chromatography. Curr Pharm Anal 2020; 16(2): 176-80.
[http://dx.doi.org/10.2174/1573412914666181017151551]
[16]
Loutradis C, Papadopoulou E, Angeloudi E, Karagiannis A, Sarafidis P. The beneficial hemodynamic actions of SGLT-2 inhibitors beyond the management of hyperglycemia. Curr Med Chem 2020; 27(39): 6682-702.
[http://dx.doi.org/10.2174/0929867326666191029111713] [PMID: 31663470]
[17]
Gitto M, Villaschi A, Federici M, Condorelli G, Stefanini GG. The emerging role of sodium-glucose cotransporter 2 inhibitors in heart failure. Curr Pharm Des 2023; 29(7): 481-93.
[http://dx.doi.org/10.2174/1381612829666230217143324] [PMID: 36799420]
[18]
Lai S, Mangiulli M, Perrotta AM, et al. Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients on therapy with tolvaptan: A pilot study. Curr Vasc Pharmacol 2021; 19(5): 556-64.
[http://dx.doi.org/10.2174/1570161118999200918094809] [PMID: 32957887]
[19]
Japundžić-Žigon N, Lozić M, Šarenac O, Murphy D. Vasopressin & oxytocin in control of the cardiovascular system: An updated review. Curr Neuropharmacol 2019; 18(1): 14-33.
[http://dx.doi.org/10.2174/1570159X17666190717150501] [PMID: 31544693]
[20]
Rodriguez M, Hernandez M, Cheungpasitporn W, et al. Hyponatremia in heart failure: Pathogenesis and management. Curr Cardiol Rev 2019; 15(4): 252-61.
[http://dx.doi.org/10.2174/1573403X15666190306111812] [PMID: 30843491]
[21]
Iovino M, Lisco G, Giagulli VA, et al. Angiotensin II-vasopressin interactions in the regulation of cardiovascular functions. evidence for an impaired hormonal sympathetic reflex in hypertension and congestive heart failure. Endocr Metab Immune Disord Drug Targets 2021; 21(10): 1830-44.
[http://dx.doi.org/10.2174/1871530321666210319120308] [PMID: 33745438]
[22]
Guerra-Torres XE. A case report of tuberous sclerosis and autosomal dominant polycystic kidney disease in the era of tolvaptan. Curr Rev Clin Exp Pharmacol 2023; 18(3): 284-90.
[http://dx.doi.org/10.2174/2772432817666220517162012] [PMID: 35585803]
[23]
Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. Am J Med 2013; 126(10): S1-S42.
[http://dx.doi.org/10.1016/j.amjmed.2013.07.006] [PMID: 24074529]
[24]
Hitomi Y, Nagatomo Y, Yukino M, et al. Characterization of tolvaptan response and its impact on the outcome for patients with heart failure. J Cardiol 2021; 78(4): 285-93.
[http://dx.doi.org/10.1016/j.jjcc.2021.04.014] [PMID: 34039465]
[25]
Sarafidis P, Pella E, Kanbay M, Papagianni A. SGLT-2 inhibitors and nephroprotection in patients with diabetic and non-diabetic chronic kidney disease. Curr Med Chem 2023; 30(18): 2039-60.
[http://dx.doi.org/10.2174/0929867329666220825121304] [PMID: 36028970]
[26]
Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: Weighing the risks and benefits. Diabetologia 2018; 61(10): 2118-25.
[http://dx.doi.org/10.1007/s00125-018-4663-6] [PMID: 30132031]
[27]
Wang Z, Sun J, Han R, et al. Efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as monotherapy or add‐on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes Obes Metab 2018; 20(1): 113-20.
[http://dx.doi.org/10.1111/dom.13047] [PMID: 28656707]
[28]
Lin DSH, Wang TD, Buranakitjaroen P, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe. J Clin Hypertens 2021; 23(3): 556-67.
[http://dx.doi.org/10.1111/jch.14120] [PMID: 33305531]
[29]
Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S. Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension? Blood Press 2019; 28(2): 75-6.
[http://dx.doi.org/10.1080/08037051.2019.1584975] [PMID: 30806086]
[30]
Lu X, Xin Y, Zhu J, et al. Diuretic resistance prediction and risk factor analysis of patients with heart failure during hos-pitalization. Glob Heart 2022; 17(1): 33.
[http://dx.doi.org/10.5334/gh.1113] [PMID: 35837353]
[31]
Guo L, Fu B, Liu Y, Hao N, Ji Y, Yang H. Diuretic resistance in patients with kidney disease: Challenges and opportunities. Biomed Pharmacother 2023; 157: 114058.
[http://dx.doi.org/10.1016/j.biopha.2022.114058] [PMID: 36473405]
[32]
Jardim SI, Ramos dos Santos L, Araújo I, et al. A 2018 overview of diuretic resistance in heart failure. Rev Port Cardiol 2018; 37(11): 935-45.
[http://dx.doi.org/10.1016/j.repce.2018.03.021] [PMID: 30470451]
[33]
Carey RM, Whelton PK. New findings bearing on the prevention, detection and management of high blood pressure. Curr Opin Cardiol 2021; 36(4): 429-35.
[http://dx.doi.org/10.1097/HCO.0000000000000864] [PMID: 34059611]
[34]
Williams B, Mancia G, Spiering W. ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[35]
Schneider RH, Salerno J, Brook RD. 2020 International society of hypertension global hypertension practice guidelines – lifestyle modification. J Hypertens 2020; 38(11): 2340-1.
[http://dx.doi.org/10.1097/HJH.0000000000002625] [PMID: 33027117]
[36]
Perunovic T, Goetze JP. C-Type natriuretic peptide in essential hypertension. JACC Basic Transl Sci 2023; 8(5): 568-71.
[http://dx.doi.org/10.1016/j.jacbts.2023.02.007] [PMID: 37325397]
[37]
Kotanidou EP, Giza S, Tsinopoulou VR, Vogiatzi M, Galli-Tsinopoulou A. Diagnosis and management of endocrine hy-pertension in children and adolescents. Curr Pharm Des 2020; 26(43): 5591-608.
[http://dx.doi.org/10.2174/1381612826666201113103614] [PMID: 33185153]
[38]
Bryniarski P, Nazimek K, Marcinkiewicz J. Immunomodulatory potential of diuretics. Biology 2021; 10(12): 1315.
[39]
Hammoudi-Bendib N, Manamani L, Ouabdesselam S, et al. Ambulatory blood pressure monitoring in the diagnosis and management of arterial hypertension in current medical practice in algeria. Curr Hypertens Rev 2021; 17(1): 75-82.
[http://dx.doi.org/10.2174/1573402116666200324144223] [PMID: 32208121]
[40]
Filippini T, Malavolti M, Whelton PK, Naska A, Orsini N, Vinceti M. Blood pressure effects of sodium reduction: Dose–response meta-analysis of experimental studies. Circulation 2021; 143(16): 1542-67.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050371] [PMID: 33586450]
[41]
Chen Q, Zhu S, Liao J, He W. Study of acute kidney injury on 309 hypertensive inpatients with ACEI/ARB – diuretic treatment. J Natl Med Assoc 2018; 110(3): 287-96.
[http://dx.doi.org/10.1016/j.jnma.2017.06.008] [PMID: 29778133]
[42]
Ghosh S, Kumar M. Prevalence and associated risk factors of hypertension among persons aged 15–49 in India: A cross-sectional study. BMJ Open 2019; 9(12): e029714.
[http://dx.doi.org/10.1136/bmjopen-2019-029714] [PMID: 31848161]
[43]
Chrysant SG. Pathophysiology and treatment of obesity‐related hypertension. J Clin Hypertens 2019; 21(5): 555-9.
[http://dx.doi.org/10.1111/jch.13518] [PMID: 30907058]
[44]
Osuagwu U, Zeried F, Ngozika E, Al-Anazi M, Mashige K. Choroidal thickness measured by ocular coherence tomography (SDOCT) and body mass index in healthy Saudi Women: A cross-sectional controlled study. Curr Med Imaging Rev 2022; 18(6): 666-73.
[http://dx.doi.org/10.2174/1573405618666220131105957] [PMID: 35100959]
[45]
Luyckx VA, Brenner BM. Clinical consequences of devel-opmental programming of low nephron number. Anat Rec 2020; 303(10): 2613-31.
[http://dx.doi.org/10.1002/ar.24270] [PMID: 31587509]
[46]
Husain K, Ansari RA, Ferder L. Alcohol-induced hypertension: Mechanism and prevention. World J Cardiol 2014; 6(5): 245-52.
[http://dx.doi.org/10.4330/wjc.v6.i5.245] [PMID: 24891935]
[47]
Acin MT, Rueda JR, Saiz LC, et al. Alcohol intake reduction for controlling hypertension. Cochrane Database Syst Rev 2020; 9(9): CD010022.
[PMID: 32960976]
[48]
Kalisch-Smith JI, Ved N, Sparrow DB. Environmental risk factors for congenital heart disease. Cold Spring Harb Perspect Biol 2020; 12(3): a037234.
[http://dx.doi.org/10.1101/cshperspect.a037234] [PMID: 31548181]
[49]
Youash S, Sharma V. Depression, antidepressants and hypertensive disorders of pregnancy: A systematic review. Curr Drug Saf 2019; 14(2): 102-8.
[http://dx.doi.org/10.2174/1574886314666190121144711] [PMID: 30666916]
[50]
Calvi A, Fischetti I, Verzicco I, et al. Antidepressant drugs effects on blood pressure. Front Cardiovasc Med 2021; 8: 704281.
[http://dx.doi.org/10.3389/fcvm.2021.704281] [PMID: 34414219]
[51]
Bioletto F, Bollati M, Lopez C, et al. Primary aldosteronism and resistant hypertension: A pathophysiological insight. Int J Mol Sci 2022; 23(9): 4803.
[http://dx.doi.org/10.3390/ijms23094803] [PMID: 35563192]
[52]
Boutari C, Georgianou E, Sachinidis A, et al. Renovascular hypertension: Novel insights. Curr Hypertens Rev 2020; 16(1): 24-9.
[http://dx.doi.org/10.2174/18756506OTgxsMTM8TcVY] [PMID: 31038069]
[53]
Farag SM, Rabea HM, Abdelrahim MEA, Mahmoud HB. Target blood pressure and combination therapy: Focus on angiotensin receptor blockers combination with either calcium channel blockers or beta blockers. Curr Hypertens Rev 2022; 18(2): 138-44.
[http://dx.doi.org/10.2174/1573402118666220627120254] [PMID: 36508272]
[54]
Maideen NMP, Balasubramanian R, Muthusamy S. A comprehensive review of the pharmacologic perspective on loop diuretic drug interactions with therapeutically used drugs. Curr Drug Metab 2022; 23(3): 188-99.
[http://dx.doi.org/10.2174/1389200223666220401092112] [PMID: 35366769]
[55]
Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros V. Hypertension in metabolic syndrome: Novel insights. Curr Hypertens Rev 2020; 16(1): 12-8.
[http://dx.doi.org/10.2174/18756506OTgw7ODElTcVY] [PMID: 30987573]
[56]
Kotfis K, Lechowicz K, Drożdżal S, et al. COVID-19—The potential beneficial therapeutic effects of spironolactone during SARS-CoV-2 infection. Pharmaceuticals 2021; 14(1): 71.
[http://dx.doi.org/10.3390/ph14010071] [PMID: 33477294]
[57]
Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med 2020; 250(4): 271-8.
[http://dx.doi.org/10.1620/tjem.250.271] [PMID: 32321874]
[58]
Lechowicz K, Drożdżal S, Machaj F, et al. COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med 2020; 9(6): 1917.
[http://dx.doi.org/10.3390/jcm9061917] [PMID: 32575380]
[59]
Liaudet L, Szabo C. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease. Crit Care 2020; 24(1): 318.
[http://dx.doi.org/10.1186/s13054-020-03055-6] [PMID: 32513242]
[60]
Haas MJ, Jurado-Flores M, Hammoud R, et al. The effects of known cardioprotective drugs on proinflammatory cytokine secretion from human coronary artery endothelial cells. Am J Ther 2019; 26(3): e321-32.
[http://dx.doi.org/10.1097/MJT.0000000000000648] [PMID: 29232287]
[61]
Moore BB, Moore TA. Viruses in idiopathic pulmonary fibrosis. Etiology and exacerbation. Ann Am Thorac Soc 2015; 12(S2): S186-92.
[http://dx.doi.org/10.1513/AnnalsATS.201502-088AW] [PMID: 26595738]
[62]
Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): An update. Cureus 2020; 12(3): e7423.
[http://dx.doi.org/10.7759/cureus.7423] [PMID: 32337143]
[63]
AlRyalat SA, Al-Ryalat N, Malkawi L, et al. Radiology during the COVID-19 pandemic: Mapping radiology literature in 2020. Curr Med Imaging Rev 2023; 19(2): 175-81.
[http://dx.doi.org/10.2174/1573405618666211230105631] [PMID: 34967299]
[64]
Palazzuoli A, Tecson KM, Vicenzi M, et al. Usefulness of combined renin-angiotensin system inhibitors and diuretic treatment in patients hospitalized with COVID-19. Am J Cardiol 2022; 167: 133-8.
[http://dx.doi.org/10.1016/j.amjcard.2021.12.004] [PMID: 35027137]
[65]
Lau S, Lau KR, Rathman L, Roberts JD. The efficacy, safety, and cost savings of high dose IV diuretics for heart failure patients in an outpatient setting with limited hospital bed space due to Covid-19. J Card Fail 2023; 29(4): 669.
[http://dx.doi.org/10.1016/j.cardfail.2022.10.302]
[66]
Abdelmonem R, Elhabal SF, Abdelmalak NS, El-Nabarawi MA, Teaima MH. Formulation and characterization of acetazolamide/carvedilol niosomal gel for glaucoma treatment: In vitro, and in vivo study. Pharmaceutics 2021; 13(2): 221.
[http://dx.doi.org/10.3390/pharmaceutics13020221] [PMID: 33562785]
[67]
Sarhan A, Rokne J, Alhajj R. Glaucoma detection using image processing techniques: A literature review. Comput Med Imaging Graph 2019; 78: 101657.
[http://dx.doi.org/10.1016/j.compmedimag.2019.101657] [PMID: 31675645]
[68]
Olivieri DJ, Lynch MG, Cockerham GC, Greenberg PB. A survey of glaucoma surgery practice patterns in the Veterans Health Administration. Mil Med 2020; 185(7-8): e972-6.
[http://dx.doi.org/10.1093/milmed/usaa033] [PMID: 32412083]
[69]
Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying “target” intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol 2018; 66(4): 495-505.
[http://dx.doi.org/10.4103/ijo.IJO_1130_17] [PMID: 29582808]
[70]
Popovic M, Schlenker MB. Angle-closure glaucoma in a myopic patient precipitated by sexual excitation: A case report. J Curr Glaucoma Pract 2018; 12(3): 142-4.
[http://dx.doi.org/10.5005/jp-journals-10078-1238] [PMID: 31354207]
[71]
Wang R, Gao Y, Liu A, Zhai G. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: Challenges analysis and recent advances. J Drug Target 2021; 29(7): 687-702.
[http://dx.doi.org/10.1080/1061186X.2021.1878366] [PMID: 33474998]
[72]
Van Berkel MA, Elefritz JL. Evaluating off-label uses of acetazolamide. Am J Health Syst Pharm 2018; 75(8): 524-31.
[http://dx.doi.org/10.2146/ajhp170279] [PMID: 29626002]
[73]
Hayashi K, Yoshida M, Sato T, Manabe S, Yoshimura K. Intraocular pressure elevation after cataract surgery and its prevention by oral acetazolamide in eyes with pseudoexfoliation syndrome. J Cataract Refract Surg 2018; 44(2): 175-81.
[http://dx.doi.org/10.1016/j.jcrs.2017.11.017] [PMID: 29525617]
[74]
Maggi L, Urru C, Friuli V, et al. Synthesis and characterization of carvedilol-etched halloysite nanotubes composites with enhanced drug solubility and dissolution rate. Molecules 2023; 28(8): 3405.
[http://dx.doi.org/10.3390/molecules28083405] [PMID: 37110635]
[75]
Sopyan I, Layyareza RT, Megantara S, Marvita SS. Carvedilol solubility enhancement by multicomponent crystallization with coformers of benzoic acid, isonicotinamide, and saccharin. Pharmacia 2023; 70(2): 283-90.
[http://dx.doi.org/10.3897/pharmacia.70.e98177]
[76]
Souto EB, Dias-Ferreira J, López-Machado A, et al. Advanced formulation approaches for ocular drug delivery: State-of-the-art and recent patents. Pharmaceutics 2019; 11(9): 460.
[http://dx.doi.org/10.3390/pharmaceutics11090460] [PMID: 31500106]
[77]
Moiseev RV, Morrison PWJ, Steele F, Khutoryanskiy VV. Penetration enhancers in ocular drug delivery. Pharmaceutics 2019; 11(7): 321.
[http://dx.doi.org/10.3390/pharmaceutics11070321] [PMID: 31324063]
[78]
Rahić O, Tucak A, Omerović N, et al. Novel drug delivery systems fighting glaucoma: Formulation obstacles and solutions. Pharmaceutics 2020; 13(1): 28.
[http://dx.doi.org/10.3390/pharmaceutics13010028] [PMID: 33375224]
[79]
Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr 2019; 13(1): 364-72.
[http://dx.doi.org/10.1016/j.dsx.2018.10.008] [PMID: 30641727]
[80]
Gharravi AM, Jafar A, Ebrahimi M, et al. Current status of stem cell therapy, scaffolds for the treatment of diabetes mellitus. Diabetes Metab Syndr 2018; 12(6): 1133-9.
[http://dx.doi.org/10.1016/j.dsx.2018.06.021] [PMID: 30168429]
[81]
Wang R, Zhou Y, Zhang Y, Li S, Pan R, Zhao Y. A three-gene-based type 1 diabetes diagnostic signature. Curr Pharm Des 2021; 27(24): 2827-33.
[http://dx.doi.org/10.2174/1381612826666201217143403] [PMID: 33334280]
[82]
de Medeiros Fernandes TAA, de Azevedo JCV, Cavalcante GA, et al. Biology and natural history of type 1 diabetes mellitus. Curr Pediatr Rev 2023; 19(3): 253-75.
[http://dx.doi.org/10.2174/1573396318666220409001955] [PMID: 36045526]
[83]
Papaetis GS. Empagliflozin and the diabetic kidney: Pathophysiological concepts and future challenges. Endocr Metab Immune Disord Drug Targets 2021; 21(9): 1555-89.
[http://dx.doi.org/10.2174/1871530321999201214233421] [PMID: 33319678]
[84]
Karangelis D, Mazer CD, Stakos D, et al. Cardio-protective effects of sodium-glucose co-transporter 2 inhibitors: Focus on heart failure. Curr Pharm Des 2021; 27(8): 1051-60.
[http://dx.doi.org/10.2174/1381612826666201103122813] [PMID: 33143620]
[85]
Papazafiropoulou AK, Melidonis A, Antonopoulos S. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on cardiorenal and metabolic outcomes in people without diabetes. Curr Pharm Des 2021; 27(8): 1035-42.
[http://dx.doi.org/10.2174/1381612826666200909142126] [PMID: 32912116]
[86]
Banerjee D, Rosano G, Herzog CA. Management of heart failure patient with CKD. Clin J Am Soc Nephrol 2021; 16(7): 1131-9.
[http://dx.doi.org/10.2215/CJN.14180920] [PMID: 33495289]
[87]
Trujillo H, Caravaca-Fontán F, Caro J, Morales E, Praga M. The forgotten antiproteinuric properties of diuretics. Am J Nephrol 2021; 52(6): 435-49.
[http://dx.doi.org/10.1159/000517020] [PMID: 34233330]
[88]
Lv P, Cai Y, Luo J, Chen K. Recent advances in the design and synthesis of small molecule carbonic anhydrase IX in-hibitors. Curr Top Med Chem 2022; 22(7): 550-60.
[http://dx.doi.org/10.2174/1568026622666220215104312] [PMID: 35168506]
[89]
Schulze PC, Bogoviku J, Westphal J, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 2022; 146(4): 289-98.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.122.059038] [PMID: 35766022]
[90]
Puglisi S, Rossini A, Poli R, et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol 2021; 12: 738848.
[http://dx.doi.org/10.3389/fendo.2021.738848] [PMID: 34745006]
[91]
Anan G, Hirose T, Kikuchi D, et al. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation. Pharmacol Res 2022; 186: 106524.
[http://dx.doi.org/10.1016/j.phrs.2022.106524] [PMID: 36349594]
[92]
Afify H, Gonzalez-Morales U, Asmar A, Alvarez CA, Mansi IA. Association of thiazide diuretics with diabetes progression, kidney disease progression, cardiovascular outcomes, and death among patients with diabetes who initiate statins. Am J Cardiol 2023; 203: 274-84.
[http://dx.doi.org/10.1016/j.amjcard.2023.07.057] [PMID: 37516035]
[93]
Weeda ER, Cassarly C, Brinton DL, Shirley DW, Simpson KN. Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors. J Diabetes Complications 2019; 33(8): 567-71.
[http://dx.doi.org/10.1016/j.jdiacomp.2019.05.001] [PMID: 31176543]
[94]
Domingo M, Ruiz-Cueto M, Teis A, Lupón J, Alonso N, Bayés-Genís A. SGLT2i and loop diuretic withdrawal or downtitration in heart failure. Rev Esp Cardiol 2023; 76(11): 943-5.
[http://dx.doi.org/10.1016/j.rec.2023.06.002] [PMID: 37331585]
[95]
Watson KE, Dhaliwal K, Robertshaw S, et al. Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: A modified delphi process. Am J Kidney Dis 2023; 81(5): 564-74.
[http://dx.doi.org/10.1053/j.ajkd.2022.10.012] [PMID: 36470530]
[96]
Shao SC, Su YC, Lai ECC, et al. Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan. Diabetes Metab 2022; 48(1): 101318.
[http://dx.doi.org/10.1016/j.diabet.2022.101318] [PMID: 35017100]
[97]
Svensen C. Electrolytes and diuretics. In: Pharmacology and Physiology for Anesthesia.: Elsevier 2019; pp. 814-35.
[http://dx.doi.org/10.1016/B978-0-323-48110-6.00042-9]
[98]
Felker GM, Ellison DH, Mullens W, et al. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. Journal of the American College of Cardiology 2020; 75(10): 1178-95.
[http://dx.doi.org/10.1016/j.gloepi.2020.100025]
[99]
Charkos TG, Liu Y, Yang S. Thiazide diuretics and risk of hip fracture: A Bayesian meta-analysis of cohort studies. Global Epidemiology 2020; 2: 100025.
[100]
Werny D, Taplin C, Bennett JT. Disorders of carbohydrate metabolism. In: In Avery’s Diseases of the Newborn. Elsevier 2018; pp. 1403-16.
[http://dx.doi.org/10.1016/B978-0-323-40139-5.00099-1]
[101]
VanBaak KD, Nally LM, Finigan RT, et al. Wilderness Medical Society clinical practice guidelines for diabetes management. Wilderness Environ Med 2019; 30(4): S121-40.
[http://dx.doi.org/10.1016/j.wem.2019.10.003] [PMID: 31753543]
[102]
van Baar MJB, Scholtes RA, van Raalte DH. SGLT2 inhibitors’ interaction with other renoactive drugs in type 2 diabetes patients: Still a lot to learn. Kidney Int 2019; 96(2): 283-6.
[http://dx.doi.org/10.1016/j.kint.2019.03.032] [PMID: 31331468]
[103]
Laliberte B, Reed BN, Devabhakthuni S, et al. Observation of patients transitioned to an oral loop diuretic before discharge and risk of readmission for acute decompensated heart failure. J Card Fail 2017; 23(10): 746-52.
[http://dx.doi.org/10.1016/j.cardfail.2017.06.008] [PMID: 28688888]
[104]
Kasama S, Toyama T, Kurabayashi M. Comparative effects of long and short-acting loop diuretics on mortality in patients with chronic heart failure. Int J Cardiol 2017; 244: 242-4.
[http://dx.doi.org/10.1016/j.ijcard.2017.06.010] [PMID: 28645802]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy